Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00928018 · ClinicalTrials.gov registry record · Phase 3

Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

A Phase 3 study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 3
Development phase
139
Enrollment target

NCT00928018: Completed Phase 3 study, sponsored by Dana-Farber Cancer Institute.

NCT00928018 is a Phase 3 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 139 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00928018, a Phase 3 study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 3
Development phase
139 participants
Enrollment target

Study Summary

This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti-lymphoma activity, their use after transplantation may lead to a decreased risk of relapse and hence better transplantation outcome.

Interventions

  • DRUG Sirolimus
  • DRUG Tacrolimus
  • DRUG Methotrexate
  • DRUG Cyclosporine
  • DRUG MMF

Trial Details

FieldValue
Enrollment Target 139 participants
Start Date 2009-06
Est. Completion 2014-11
Phase Phase 3
Dana-Farber Cancer Institute

781 total trials

What the finished NCT00928018 record still lists

NCT00928018 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.

NCT00928018 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00928018 about?

NCT00928018 is a clinical study titled "Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma". This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti...

What is the current status of trial NCT00928018?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2009-06. Estimated completion is 2014-11.

What interventions are being tested in trial NCT00928018?

The interventions under investigation include: Sirolimus (DRUG), Tacrolimus (DRUG), Methotrexate (DRUG), Cyclosporine (DRUG), MMF (DRUG).

Who is sponsoring clinical trial NCT00928018?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT00928018's enrollment target sits among peer trials

139 1577th of 2000 higher than 424 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05645380 · 139 participants · Phase 2

    Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

  • NCT06239272 · 139 participants · Phase 1

    NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • NCT06252220 · 139 participants · Phase 1

    First in Human Study in Subjects With Obesity, But Otherwise Healthy

  • NCT06537128 · 139 participants · NA

    Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00928018, the US trial registry maintained by the National Library of Medicine. NCT00928018 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.